Brand-Ad-30-6
 IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 6671 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed15221    
    Printed193    
    Emailed13    
    PDF Downloaded39    
    Comments [Add]    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2001  |  Volume : 67  |  Issue : 6  |  Page : 320--323

Evaluation and therapeutic outcome of palpable purpura


Dept of Dermatology, Kasturba Medical College, Manipal 576119, Karnataka, India

Correspondence Address:
Shruthakirthi D Shenoi
Dept of Dermatology, Kasturba Medical College, Manipal 576119, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 17664788

Rights and PermissionsRights and Permissions

Palpable purpura is the clinical hallmark of leukocytoclastic vasculitis. Its etiology can be varied but often is elusive. Henoch- Schonlein purpura (HSP) is a distinct subtype of hypersensitivity vasculitis of unknown cause occurring primarily in children. IgA deposits in vessels is thought to be diagnostic of HSP. This study is aimed to evaluate the etiology, clinical manifestations and therapeutic outcome in patients with palpable purpura and to assess the relevance of IgA deposits in these patients. Thirty-six patients with palpable purpura were evaluated by history and laboratory investigations including biopsy for histopathology and direct immunotluorescence. Twenty-four patients received treatment with dapsone, steroids or a combination. All patients were followed up at first and third month and then at 6 monthly intervals for a maximum of 2 years.






[FULL TEXT] [PDF Not available]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow